TRANSTAR102-(TST001-1002)-COHORT-G
Regimen
- Experimental
- osemitamab (anti-CLDN18.2 ADCC-enhanced antibody) + nivolumab + CAPOX
Population
First-line advanced G/GEJ cancer with high/medium CLDN18.2 expression
Key finding
High/medium CLDN18.2 any PD-L1: mPFS 12.6 mo; subset CPS<5 mPFS 12.6 mo; ORR 66%+
Guideline citations
- NCCN GASTRIC (p.104)